A PHASE 2 STUDY OF SAFETY AND EFFICACY OF TEMSIROLIMUS (CCI-779) ADMINISTERED AS A SINGLE AGENT IN EAST ASIAN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

被引：0
|
作者：
Sun, Y. [1 ]
Rha, S. Y. [2 ]
Lee, S. [3 ]
Guo, J. [4 ]
Ueda, T. [5 ]
Qin, S. [6 ]
Naito, S. [7 ]
Cincotta, M. [8 ]
Tokushige, K. [9 ]
Akaza, H. [10 ]
机构：
[1] Chinese Acad Sci, Canc Hosp, Beijing, Peoples R China
[2] Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[4] Beijing Canc Hosp, Beijing, Peoples R China
[5] Chiba Canc Ctr, Chiba 2608717, Japan
[6] Nanjing Bayi Hosp, PLA Canc Ctr, Dept Med Oncol, Nanjing, Peoples R China
[7] Kyushu Univ Hosp, Fukuoka 812, Japan
[8] Pfizer Inc, Cambridge, MA USA
[9] Pfizer Inc, Tokyo, Japan
[10] Tsukuba Univ Hosp, Tsukuba, Ibaraki, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [1] A phase II study of temsirolimus (CCI-779) in patients with advanced leukemias.
    Yee, KWL
    Garcia-Manero, G
    Thomas, D
    Ani, FRK
    Verstovsek, S
    Andreeff, M
    Dancey, JE
    Giles, FJ
    [J]. BLOOD, 2004, 104 (11) : 214B - 214B
  • [2] Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinoma†
    Sun, Yan
    Rha, Sun
    Lee, Se-Hoon
    Guo, Jun
    Ueda, Takeshi
    Qin, Shukui
    Naito, Seiji
    Cincotta, Maria
    Tokushige, Kota
    Akaza, Hideyuki
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (09) : 836 - 844
  • [3] A Phase 1 Clinical Study of Temsirolimus (CCI-779) in Japanese Patients with Advanced Solid Tumors
    Fujisaka, Yasuhito
    Yamada, Yasuhide
    Yamamoto, Noboru
    Horiike, Atsushi
    Tamura, Tomohide
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (08) : 732 - 738
  • [4] Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, TE
    Geyer, SM
    Ghobrial, I
    Inwards, DJ
    Fonseca, R
    Kurtin, P
    Ansell, SM
    Luyun, R
    Flynn, PJ
    Morton, RF
    Dakhil, SR
    Gross, H
    Kaufmann, SH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5347 - 5356
  • [5] A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer
    Hidalgo, Manuel
    Buckner, Jan C.
    Erlichman, Charles
    Pollack, Marilyn S.
    Boni, Joseph P.
    Dukart, Gary
    Marshall, Bonnie
    Speicher, Lisa
    Moore, Laurence
    Rowinsky, Eric K.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (19) : 5755 - 5763
  • [6] Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, T
    Geyer, S
    Ghobrial, I
    Inwards, D
    Fonseca, R
    Kurtin, P
    Ansell, S
    Kaufmann, S
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 65 - 65
  • [7] A phase IINCCTG "window of opportunity front-line" study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC
    Molina, Julian R.
    Mandrekar, Sumithra J.
    Rowland, Kendrith
    Reuter, Nicholas F.
    Jett, James R.
    Marks, Randolph
    Schild, Stevens E.
    Adjei, Alex A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S413 - S413
  • [8] Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma.
    Smith, JW
    Ko, YJ
    Dutcher, J
    Hudes, G
    Escudier, B
    Motzer, R
    Négrier, S
    Duclos, B
    Galand, L
    Strauss, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 385S - 385S
  • [9] A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul
    Koenig, Patricia
    Inwards, David J.
    Shah, Keith
    Witzig, Thomas E.
    [J]. BLOOD, 2009, 114 (22) : 664 - 665
  • [10] Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer
    Boni, JP
    Leister, C
    Bender, G
    Fitzpatrick, V
    Twine, N
    Stover, J
    Dorner, A
    Immermann, F
    Burczynski, ME
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) : 76 - 89
12345